Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (409)	9/30/1999 2:17:00 PM
From: ErnestPoe	Respond to of 52153

Liking GNLB at this level. Heard some good news about thier new lupus drug is coming out this month. I here they are expecting fabulous results for there phase III trial. SW

To: JOEBT1 who wrote (409)	9/30/1999 2:25:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 52153

Good point, yet according to the company's clowns they presented the data already and what the FDA wants is access to the original material. Sure a complex, but obvious, question that Coulter claims to have addressed all along. Just read their PRs and other material, or visit my pseudo biotech web page to get most of them organized: freeyellow.com This also useful (comments by Lehman Brothers including more detail on what the company says the FDA wants): lehman.com (links to Lehman tend to expire after a while; it did work today) Half-life? about 8 days according to this and similar links: udel.edu I think the refiling "issue" is a reflection of the bumbling nature of this management. I am hoping they get their act together ... soon. PB